AbbVie Q3 2024 Adj EPS $3.00 Beats $2.92 Estimate, Sales $14.46B Beat $14.28B Estimate
Portfolio Pulse from Benzinga Newsdesk
AbbVie reported Q3 2024 earnings per share of $3.00, surpassing the analyst estimate of $2.92. The company's sales reached $14.46 billion, exceeding the expected $14.28 billion and marking a 3.83% increase from the previous year.
October 30, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie reported better-than-expected Q3 2024 earnings and sales, with EPS of $3.00 beating the $2.92 estimate and sales of $14.46B surpassing the $14.28B estimate. This indicates strong financial performance and growth.
AbbVie's Q3 2024 earnings and sales exceeded analyst expectations, indicating strong financial health and potential for positive stock movement. The EPS beat by 2.74% and sales beat by 1.28% suggest robust performance, likely boosting investor confidence.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100